JINWEI | Eliciting Natural Immune Responses

About JINWEI

Shanghai Jinwei Biotechnology Co., Ltd. is a biotechnology company dedicated to pursuing innovative technologies to develop cures for people with serious and life-threatening diseases.

Our Mission

We are committed to developing first-in-class innovative drugs using lentiviral vector technology platforms and cryptic peptide technology platforms, applicable to a wide range of infectious diseases and malignant tumors.

As a participant in national-level projects led by the Ministry of Science & Technology and China National Health Commission, we actively contribute to the prevention and control of infectious diseases.

Our Technologies

Pioneering advanced platforms to elicit powerful and sustained immune responses.

Lentiviral Vector Platform

Our innovative lentiviral vectors enable dendritic cells to train immune cells to destroy infected or cancerous cells. This platform has been clinically validated and stands on over two decades of research from the Pasteur Institute in France.

Efficient transduction of dendritic cells
Sustained antigen presentation via endogenous pathway
Activation of key immune effectors with high efficacy
Non-integrating design enhances safety profile

Learn More →

In-Silico Neoantigen Identification

We combine next-generation computational methods with our lentiviral platform to identify patient-specific neoantigens for personalized cancer immunotherapy.

High-precision tumor mutation prediction
Personalized vaccine design
Integration with viral vector delivery
Accelerated development timelines

Explore the Science →

What We Do

Delivering cutting-edge therapies and services across infectious diseases, cancer, and CDMO solutions.

Therapeutic HBV Vaccine

Non-integrating lentiviral vector-based vaccine demonstrating significant efficacy in clinical studies.

Infectious Disease

HPV-Induced Cancer Vaccine

In Phase I clinical trial in the U.S., targeting cancers caused by human papillomavirus.

Oncology

HIV Vaccine (Preclinical)

Based on the same lentiviral vector platform, previously tested in Phase I/II trials in Europe.

Infectious Disease

Personalized Neoantigen Vaccine

Tailored immunotherapy using patient-specific tumor antigens delivered via lentiviral vectors.

Immunotherapy

Vector Production Facility

GMP Viral Vector Manufacturing

State-of-the-art GMP-compliant facility producing safe and reliable lentiviral vectors.

CDMO

Clinical Trial Support

End-to-End CDMO Services

From clinical trials to commercialization, supporting partners with scalable solutions.

CDMO

Research Collaboration

Collaborative R&D Programs

Partnering with hospitals and institutions like Huashan Hospital on innovative therapies.

Partnership

Regulatory Compliance

Regulatory-Compliant Development

Facilities and processes aligned with FDA, EMA, and CFDA standards.

Quality

Jinwei Highlights

High Technological Barriers

Lentiviral vector technology rooted in over 20 years of research at the Pasteur Institute.

Proven Track Record

Clinical validation in HIV and HPV cancer vaccines across Europe and the U.S.

Unmet Clinical Needs

Developing first-in-class drugs for infectious diseases and malignant tumors.

Major Partnerships

Collaborating with Huashan Hospital and national health authorities.

GMP Compliant Facilities

State-of-the-art labs and production facilities compliant with FDA, EMA, and CFDA.

Innovative Pipeline

Multiple candidates in development for cancer and chronic infectious diseases.

Latest Updates

News

April 2020

Innovative Breakthrough Non-Integrating Lentiviral Vector Therapeutic Hepatitis B Vaccine Demonstrates Significant Efficacy

April 2020

The First Zhangjiang International Summit on Cell Therapy Held to Promote the Cell Therapy Industry in China

Events

April 2020

The First Zhangjiang International Summit on Cell Therapy Held to Promote the Cell Therapy Industry in China

Learn More →

April 2020

17 Outstanding Innovative Pharmaceutical Companies Attended Symposium

Learn More →

Get in Touch

For partnership opportunities, scientific collaboration, or general inquiries, visit our official website.

Visit Official Website

China Quality Suppliers fobcompany.info

Notice for Buyers: If you are a buyer, the above information is generated by AI collection and does not constitute any advice. If necessary, please visit the corresponding official website.

For Domain Owners: If you are the domain owner and do not want to be included by fobcompany.info, please contact [email protected] via your corporate email to cancel. We will cancel your inclusion within 3 business days.

如果您是域名所有者不想被fobcompany.info收录请用企业邮箱联系[email protected] 取消收录我们将在3个工作日取消您的收录

Service Request: If you are other domain and want to be included, please contact [email protected]

如果您是其他域名合作也请联系[email protected]